InsidersTradesSigma
Follow the Relmada Therapeutics, INC. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Relmada Therapeutics, INC. has recorded 31 reports. Market capitalisation: €526.9m. The latest transaction was disclosed on 16 December 2025 (Acquisition). Among the most active insiders: TRAVERSA SERGIO. The full history is openly available.
31
Insider Decl.
n/a
Thresholds
€3m
21 ops.
Buy Volume
€165,664
3 ops.
Sell Volume
50Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 27,116 of 29,064 companies
18.1
score / 100
Value16
Quality20
FCF yld-8.7%
Earn yld-11%
EV/EBITDA·
ROE-26%
Gross mgn21%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 16 December 2025
Declarations31 total
27,500 shares@ US$4.127.3% of flowCommon StockSEC:0001213900-25-121974:0
Canonical exit: 15 Mar 2026 (T+90)
11,665 shares@ US$4.123.8% of flowCommon StockSEC:0001213900-25-121973:0
Canonical exit: 15 Mar 2026 (T+90)
136,000 shares@ US$2.2066.9% of flowCommon StockSEC:0001213900-25-106838:0
Canonical exit: 3 Feb 2026 (T+90)
272,500 shares@ US$2.2042.3% of flowCommon StockSEC:0001213900-25-106837:0
Canonical exit: 3 Feb 2026 (T+90)
500,000 shares@ US$2.2092.7% of flowCommon StockSEC:0001213900-25-106836:0
Canonical exit: 3 Feb 2026 (T+90)
90,000 shares@ US$2.2043.7% of flowCommon StockSEC:0001213900-25-106835:0
Canonical exit: 3 Feb 2026 (T+90)
80,545 shares@ US$0.626.0% of flowCommon StockSEC:0001213900-25-081837:0
Canonical exit: 24 Nov 2025 (T+90)
50,000 shares@ US$0.44226.3% of flowCommon StockSEC:0001213900-25-046087:0
Canonical exit: 14 Aug 2025 (T+90)
172,314 shares@ US$0.449610.4% of flowCommon StockSEC:0001213900-25-046085:0
Canonical exit: 14 Aug 2025 (T+90)
200,000 shares@ US$0.430327.6% of flowCommon StockSEC:0001213900-25-046088:0
Canonical exit: 14 Aug 2025 (T+90)
228,961 shares@ US$0.451371.7% of flowCommon StockSEC:0001213900-25-046086:0
Canonical exit: 14 Aug 2025 (T+90)
13,000 shares0Common StockSEC:0001213900-24-089971:0
8,194 shares@ US$2.5525.2% of flowCommon StockSEC:0001213900-24-077792:0
Canonical exit: 8 Dec 2024 (T+90)
25,000 shares@ US$2.5921.0% of flowCommon StockSEC:0001213900-24-077791:0
Canonical exit: 8 Dec 2024 (T+90)
55,579 shares@ US$2.7120.4% of flowCommon StockSEC:0001213900-24-077795:0
Canonical exit: 8 Dec 2024 (T+90)
13,000 shares@ US$2.566.3% of flowCommon StockSEC:0001213900-24-077794:0
Canonical exit: 8 Dec 2024 (T+90)
10,800 shares@ US$3.652848.5% of flowCommon StockSEC:0001213900-24-008559:0
Canonical exit: 28 Apr 2024 (T+90)
31,541 shares@ US$3.710616.2% of flowCommon StockSEC:0001213900-24-008560:0
Canonical exit: 28 Apr 2024 (T+90)
10,800 shares@ US$3.651728.3% of flowCommon StockSEC:0001213900-24-008557:0
Canonical exit: 28 Apr 2024 (T+90)
10,000 shares@ US$3.18100.0% of flowCommon StockSEC:0001213900-23-042554:0
Canonical exit: 21 Aug 2023 (T+90)
55,250 shares@ US$2.09616.5% of flowCommon StockSEC:0001213900-22-079244:0
Canonical exit: 8 Mar 2023 (T+90)
16,012 shares@ US$16.0036.6% of flowCommon StockSEC:0001213900-22-037231:0
19,800 shares@ US$3.2417.4% of flowCommon StockSEC:0001213900-22-018207:0
10,000 shares@ US$3.247.5% of flowCommon StockSEC:0001213900-22-018223:0
20,000 shares@ US$3.2414.4% of flowCommon StockSEC:0001213900-22-000761:0
25 of 31 declarations
关于 Relmada Therapeutics, INC.
Relmada Therapeutics, Inc. 是一家在纳斯达克（美国）上市的临床阶段生物制药公司，股票代码为 RLMD。对于法语投资者而言，它符合典型的高风险、高回报小型医疗保健公司的特征，其估值主要由临床执行、监管进展和融资能力驱动，而非当前产品收入。该公司成立于 2004 年，总部位于美国佛罗里达州科勒尔盖布尔斯。其战略重点是在肿瘤学和选定的中枢神经系统适应症领域开发差异化疗法，并由一支在药物开发、临床运营和监管策略方面经验丰富的管理团队提供支持。([relmada.com](https://www.relmada.com/for-investors?utm_source=openai)) Relmada 的主要项目是 NDV-01，这是一种用于非肌肉浸润性膀胱癌 (NMIBC) 的吉西他滨和多西他赛膀胱内缓释制剂。该产品旨在提供延长的膀胱暴露和受控的局部药物释放，同时简化诊室给药。该公司已披露 FDA 对两条注册途径的认可，NDV-01 正在推进一项预计于 2026 年年中启动的 3 期 RESCUE 注册项目。该项目是近期至中期内的主要价值驱动因素。Relmada 还在推进 sepranolone，这是一种调节 GABA-A 受体活性以治疗强迫行为的候选药物，计划在普拉德-威利综合征中进行 2 期试验。([relmada.com](https://www.relmada.com/?utm_source=openai)) 从竞争角度来看，Relmada 在一个拥挤的生物技术领域中运营，该领域由大型制药公司、专业肿瘤学公司和众多临床阶段同行主导。其潜在优势在于 NDV-01 基于制剂的差异化、NMIBC 的商业和医学吸引力，以及专注于未满足需求高且治疗选择有限或不理想的领域的开发策略。与此同时，该公司仍然面临开发阶段生物技术的标准风险：临床失败、安全问题、监管挫折、资金需求和稀释风险。([relmada.com](https://www.relmada.com/?utm_source=openai)) Relmada 的地理足迹主要在美国，运营集中在佛罗里达州，并在美国纳斯达克上市。近期催化剂包括 2026 年 3 月宣布的超额认购的约 160 million PIPE 融资，这增强了资产负债表，并有望支持 NDV-01 的 3 期开发。该公司还报告了 NDV-01 的 2 期数据，提供了积极的监管更新，确认 FDA 对两个独立适应症的研究设计达成一致，并发布了 2026 年第一季度业务和财务更新。对于欧洲投资者而言，RLMD 应被视为一个投机性生物技术故事，其中期结果将主要取决于即将到来的临床里程碑和监管验证，而非近期盈利能力。([relmada.com](https://www.relmada.com/for-investors/news/detail/333/relmada-therapeutics-announces-oversubscribed-160-0?utm_source=openai))
